Rituxan 2015 report




Published July 2016 • 29 Pages

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Rituxan through personal promotion in 2015 and how does this compare to its peer set in the Chronic Lymphocytic Leukemia, Follicular Lymphoma, Microscopic Polyangiitis, Non-Hodgkin’s Lymphoma, Rheumatoid Arthritis, and Wegener’s Granulomatosis markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does Genentech’s depth of coverage vary within key specialties (e.g., Rheumatology, Hematology/Oncology, Nephrology, Internal Medicine, and Medical Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Rituxan throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most detailed prescribers and top paid speakers/consultants for Rituxan in 2015?

Data Sources and Methodology:

  • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
  • Over 20,400 paid interactions across 5,600 physicians made on behalf of Rituxan were carefully examined to support our analysis. In addition, interaction data from 20 peer products (e.g. Actemra, Arzerra, Cimzia, Enbrel, Gazyva, Humira, Ilaris, Imbruvica, Intron A, Kineret, Orencia, Otrexup, Rasuvo, Rayos, Remicade, Simponi, Treanda, Xeljanz, Zevalin, and Zydelig) was leveraged to provide benchmarking and market insights.